Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COLUMN
COLUMN
-
Maurer's Healthcare Insight (43)
July 14, 2003
-
Maurer's Healthcare Insight (42)
June 16, 2003
-
Maurer's Healthcare Insight (41)
May 19, 2003
-
Maurer's Healthcare Insight (40)
April 28, 2003
-
Maurer's Healthcare Insight (39)
April 14, 2003
-
Maurer's Healthcare Insight (Special)
March 24, 2003
-
Maurer's Healthcare Insight (Special)
March 17, 2003
-
Maurer's Healthcare Insight (38)
February 17, 2003
-
Maurer's Healthcare Insight (37)
January 20, 2003
-
Maurer's Healthcare Insight (36)
December 2, 2002
-
Maurer's Healthcare Insight (35)
November 11, 2002
-
Maurer's Healthcare Insight (33)
September 2, 2002
-
Maurer's Healthcare Insight (32)
August 5, 2002
-
Maurer's Healthcare Insight (31)
July 22, 2002
-
Maurer's Healthcare Insight (30)
July 1, 2002
-
Maurer's Healthcare Insight (29)
June 3, 2002
-
Maurer's Healthcare Insight (28)
May 20, 2002
-
Maurer's Healthcare Insight (27)
April 29, 2002
-
Maurer's Healthcare Insight (27)
April 15, 2002
-
Maurer's Healthcare Insight (26)
March 18, 2002
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…